Powering a global health revolution.
Chardan pioneered the emergence of Biotech SPACs and we continue to define the sector today.
Broad coverage, deep insight, and a smart approach.
Chardan is deeply immersed in the businesses that are changing the course of healthcare. Our practice is lead by preeminent scientists, physicians and thought leaders in the field and informed by a disciplined research group. We deliver value across the SPAC lifecycle including after-merger support, research coverage, investor introductions and advisory work.
Advising on critical issues like de-risking the deal and providing a framework for securing financial commitments, Chardan also coordinated a roadshow that lead to the acquisition of $105MM in investment with an addition $35MM bridge for R&D. We drove the deal and helped to successfully complete the smooth transition.
Many possibilities, one company to get you there.
Chardan serves as both advisor and partner in helping to both successfully raise capital through an IPO and then in identifying target acquisition candidates.
Finance your growth strategy by taking your company public through a flexibly structured merger with a Special Purpose Acquisition Company (SPAC).
Combine participation in high-growth, disruptive businesses with the confidence and security of cash held in trust and equity upside.
Chardan’s Healthcare SPAC Leadership
We've received your information, and we're processing your request.